67 results about "Cellular lipid" patented technology

Methods, vessels, and systems are provided for processing lipids contained in biomass, such as organisms grown in aqueous media or wastes in aqueous media, to produce fatty acid esters as components of a fuel, such as biofuels. The methods described herein are able to efficiently convert cellular lipids to biofuels from lipid-containing biomass such as algae.

A method for determination of at least one of the lipid species in a biological sample comprising subjecting the sample to lipid extraction to obtain a lipid extract and subjecting the resulting lipid extract to multidimensional electrospray ionization mass spectrometry using either precursor ion or neutral loss scanning (or both) of all naturally occurring aliphatic chains, lipid fragments and precursor ions leading to observed fragments to generate a multidimensional matrix whose contour densities provides structural and quantitative information directly without chromatography. A method for determination of lipid content and/or lipid molecular species composition and quantity directly from lipid extracts of a biological sample comprising subjecting said lipid extract to electrospray ionization multidimensional mass spectrometry by comparisons to standards and algorithms described herein.

The invention discloses a siRNA interference-based anti-HBV gene-based drug mediated by complex carriers. Based on the characteristic of HBV and expression products thereof, active epitope protein in HBsAg expressed by HBV is biologically linked with cationic liposome and specially binds with hepatic cell surface receptors with the help of the epitope protein in the HBsAg to induce RNAi to enter hepatic cells; meanwhile, the meltability of bilayers of the cationic liposome and the cytolipin is used for increasing the efficiency of an siRNA expressed carrier entering into the hepatic cells. The drug of the invention can improve the effectiveness of the siRNA, biological stability in the human body, safety and effective targeting delivery and can be used in the clinical treatment.

Disclosed is an anti-tumor drug with nor-icariin as the effective ingredient. Pharmacological test effect proves that the nor-icariin has the activity to inhibit the production of cellular lipid, can reduce the production of cellular fatty acid by inhibiting the activity of FAS, has a function of inhibiting the production and causing withering of microvascular endothelial cells, shows a broad-spectrum anti-tumor function in a cytotoxicity test of thirty-three tumor cell strains of a human body, and shows a function in strongly inhibiting the production of tumor, such as prostate cancer cells LnCAP, lung cancer cells NCI-H23 and colon cancer cells HCT-116 of a human body in a tumor transplantation nude mice model test. A pharmacokinetics test of the nor-icariin in the body of a little mouse proves that the nor-icariin can be kept with a certain concentration, good for better anti-humor effect. The acute toxicity test of the nor-icariin in the body of the mouse shows nontoxicity; therefore the nor-icariin is proved to be a newly-developed broad spectrum anti-humor drug with broad development prospect.

The invention provides modified DGAT1 proteins that are modified in the N-terminal region upstream of the acyl-Co A binding site. The modified DGAT proteins show enhanced activity, without reduced protein accumulation when expressed in cells. The modified DGAT1 proteins of the invention can be expressed in cells to increase cellular lipid accumulation and/or modify the cellular lipid profile. The invention also provides polynucleotides encoding the modified DGAT1 proteins, cells and compositions comprising the polynucleotides or modified DGAT proteins, and methods using the modified DGAT1 proteins to produce oil.

Disclosed herein are peptides with domains that promote lipid efflux from cells and optionally possess at least one anti-inflammatory domain or a domain that stimulates LCAT activity. Provided herein are methods of using the peptides to treat or inhibit diseases including dyslipidemic disorders, stroke and myocardial infarction. Also provided are methods of detecting plaque in vessels using the labeled peptides of the present invention.

Disclosed are methods and compositions for increasing the triacylglycerol content of a cell by up-regulating diacylglycerol acyltransferase and down-regulating triacylglycerol lipase. In some embodiments, a DGA1 protein is expressed and a native TGL3 gene is knocked out, thereby increasing the synthesis of triacylglycerol and decreasing its consumption, respectively.

A method for determination of at least one of the lipid species in a biological sample comprising subjecting the sample to lipid extraction to obtain a lipid extract and subjecting the resulting lipid extract to multidimensional electrospray ionization mass spectrometry using either precursor ion or neutral loss scanning (or both) of all naturally occurring aliphatic chains, lipid fragments and precursor ions leading to observed fragments to generate a multidimensional matrix whose contour densities provides structural and quantitative information directly without chromatography. A method for determination of lipid content and/or lipid molecular species composition and quantity directly from lipid extracts of a biological sample comprising subjecting said lipid extract to electrospray ionization multidimensional mass spectrometry by comparisons to standards and algorithms described herein.

In some embodiments, the present invention provides a method of elevating lipid content in vegetative (non-seed) plant or algae cells, plant tissues, or whole plants by genetically modifying the plant or algae to express a lipid droplet-associated protein or polypeptide (such as fat-specific protein 27) of mammalian origin. Also provided are genetically-modified plant or algae cells, plant tissues, or whole plants with elevated cellular lipid content, expressing a lipid droplet-associated protein or polypeptide (such as fat-specific protein 27) of mammalian (e.g. human) origin.

The invention discloses a TRAF4 (Tumor Necrosis Factor Receptor-associated Factor 4) and application of an inhibitor thereof in preparing medicine for treating fatty liver and associated diseases. Bytaking a human normal liver L02 cell line, a TRAF2 knocked-down L02 cell line, primary hepatocyte and TRAF4 knocked-down primary hepatocyte as research objects and stimulating and inducing a liver cell lipid accumulation model by PA (Palmitic Acid) and OA (Oleic Acid), functions of a TRAF4 gene can be researched. The research discovers that when expression of the TRAF4 is reduced, L02 cell lipid accumulation stimulated and induced by the PA and the OA is remarkably reduced, i.e., the TRAF4 gene is capable of promoting occurrence and development of the fatty liver and the associated diseases, so that the TRAF4 provides a target for developing the medicine for preventing, relieving and/or treating the fatty liver and the associated diseases.

The invention discloses a method for detecting the influences of a buccal cigarette product on lipid peroxidation of cells. The method comprises the following steps: (1) preprocessing test samples; (2) preparing a human oral keratinocyte single cell suspension; (3) calculating the cell concentration of the human oral keratinocyte single cell suspension; (4) inoculating the human oral keratinocyte single cell suspension with cells; (5) grouping the test samples; (6) setting the test dosage of the test samples; (7) preparing a test sample culture product; (8) incubating the test samples; (9) collecting test sample incubated products; (10) cracking and centrifuging the test sample incubated products; (11) diluting a standard product; (12) detecting the test samples; and (13) calculating the malondialdehyde content. The effective treatment of the samples, the optimal setting of the detection dosage and the correct selection of the target cells make the method accurately and effectively detect the influences of the buccal cigarette product on the lipid peroxidation of the cells.

Experiment researches find that the expression quantity of GPR31 protein is gradually increased along with the prolonging of tissue ischemia time, and a positively related relationship exists between the expression quantity of GPR31 protein and tissue ischemia reperfusion injury severity. The overexpression of GPR31 can increase the activity of liver cells, cardiac muscle cells and kidney cells caused by H/R treatment. Moreover, the decrease of GPR31 expression in the liver cells can inhibit cellular lipid accumulation caused by palmitate and oleic acid stimulation. The overexpression of GPR31 in the cardiac muscle cells can increase cardiac hypertrophy caused by Angiotensin II. Therefore, the GPR31 inhibitor can be used for preparing drugs, and the drugs can be used for curing related diseases of ischemia reperfusion injury, cardiac hypertrophy and related diseases and liver metabolism diseases.

The invention provides a novel DGAT1 protein with improved properties over known DGAT proteins, particularly known DGAT1 proteins from plants. The novel DGAT1 protein of the invention can be expressed in cells to increase cellular lipid accumulation. Expression of the DGAT1 protein of the invention in cells results in a higher level of lipid than any of several other plant DGAT1 proteins tested by the applicants. The invention provides polynucleotides encoding the novel DGAT1 protein of SEQ ID NO:39, constructs, cells, plant, plant parts and progeny comprising the polynucleotides, and methods of use of the polynucleotides and polypeptides of the invention.

The invention discloses application of novel loquat leaf sesquiterpene glycoside in relieving liver cell lipid deposition, and also discloses application in preparation of drugs and health-care foodsfor preventing or treating non-alcoholic fatty liver. The name of the sesquiterpene glycoside is nerolidol-3-O-alpha-L-arabinopyranosyl-(1->4)-alpha-L-rhamnopyranosyl-(1-> 2)-[alpha-L-rhamnopyranosyl-(1-> 6)]-beta-D-glucopyranoside.

The invention discloses an application of an ethyl acetate extract of emblic leafflower fruits in prevention and treatment of atherosclerosis, and provides an application of the ethyl acetate extractof emblic leafflower fruits in preparation of any one or more of the following products: an in-vivo and in-vitro oxidation inhibitor for low-density lipoprotein; an inhibitor for macrophage and vascular endothelial cell damage caused by oxidized low-density lipoprotein; a macrophage foaming transition inhibitor; a macrophage inflammatory factor secretion inhibitor; a macrophage lipid efflux promoter; an ABCA1 transport protein promoter; and an ABCG1 transport protein promoter. Emblic leafflower fruit resources are rich, so that the ethyl acetate extract of the emblic leafflower fruits is easyto prepare. The extract is developed into food additives, health foods, medicines and other related products with the effect of preventing and treating atherosclerosis, and has very high application value.

The invention discloses an application of a protein signal transduction regulatory factor 14 in the preparation of drugs for treating fatty liver and related diseases, and belongs to new uses of RGS14. A result of the research of the functions of an RGS14 gene through a palmitate (PA) and oleic acid (OA) stimulus-induced liver cell lipid accumulation model with a human normal liver L02 cell line and an RSG14 over-expression L02 cell line as research objects shows that the RSG14 over-expression can significantly improve the lipid accumulation in liver cells, so the RGS14 can protect the liver cells from being subjected to lipoid denaturation. The RGS14 is a body endogenous protein, so the RGS14 has an excellent safety when used as a drug.